suite.
`'ll'fii‘) © 1998 Nature Publishing Group http://www.nature.com/naturebiotechnology
`COMMENTARY
`
`l
`Genentech is poised—for an anti—cancer breakthrough
`
`Russ Hoyle
`
`For the better part of a decade, the excite-
`Ever since the freewheeling G. Kirk Raab was
`room over monoclonal
`therapies cooled.
`forced to step down three years ago as head of
`Genentech (S. San Francisco, CA), his succes-
`Then researchers figured out how to replace
`the problematic mouse-contaminated por-
`sor Arthur D. Levinson has been under pres-
`tions ofmolecules with replacement material
`sure to beef up the company’s research and
`from human proteins. Genentech’s new
`development programs and produce exciting
`“humanized”
`experimental monoclonal
`new product lines.
`antibody therapy targeted the growth factor
`Levinson has gotten off to a good start.
`receptor gene HERZ/neu, which was known
`Genentech, which was bought out by
`to proliferate on the surface of cancerous
`Hoffman-LaRoche (Basel)
`in l990, began
`breast tissue cells in deadly late-stage cases of
`marketing Rituxin,
`the
`only federally
`the disease. The antibody worked by attach-
`approved monoclonal antibody for the treat-
`ment of cancer.
`last November. With the
`ing itself to the HERZ receptor, blocking the
`announcement this September that a US
`genetic signals that cause diseased cells to
`reproduce and in some cases killing off the
`Food and Drug Administration (FDA;
`cancer cells.
`Rockville, MD) advisory committee voted to
`approve Genentech’s experimental Herceptin
`The potential market was small. but in
`dire need. Some 1.6 million American
`monoclonal
`antibody,
`Levinson
`and
`women currently have breast cancer. There
`Genentech are now poised for another
`are 180,000 new cases in the U.S. each year.
`impressive therapeutic breakthrough for
`Of the roughly 164,000 metastatic cases.
`late-stage treatment of breast cancer. The
`some 25—30% involved overexpression of the
`FDA is expected to approve Herceptin by the
`end of the year.
`HERZ gene. As early as 1995, Genentech was
`For Levinson, the timing could not be
`swamped by demand for the highly targeted,
`yet—to—be-approved new drug and teamed up
`more serendipitous. When he took over the
`with patient advocacy groups to design a lot»
`company in 1995, what was then known as
`tery system to equitably distribute a limited
`Herz was among the hottest new properties
`supply of the investigational drug to severely
`in Genentech’s pipeline. It was also believed
`affected patients.
`that Levinson’s fate would probably depend
`on
`how successfully
`he
`beefed
`up
`But it wasn’t until 1996, less than a year
`after Levinson had taken the reins from Raab,
`Genentech’s flagging research programs and
`that Genentech announced favorable results
`brought
`innovative new pharmaceutical
`of the initial tests of its experimental therapy.
`products to market. Under the terms of the
`At an April scientific meeting, Genentech
`buyout, Hoffman-LaRoche, which owns
`67% of Genentech,
`is due to exercise its
`clinical researcher Thomas 'IWadell reported
`that 5 of44 women treated with the new anti~
`option to purchase 100% of the company
`next year.
`HERZ antibody alone experienced significant
`tumor reduction. In combination with other
`The development of an effective mono-
`chemotherapy, positive responses occurred in
`clonal antibody targeting the HERZ onco—
`nine out of 36 cases, or 25% ofthose treated.
`gene, a marker for the fatal spread of late-
`term breast cancer, has been a result of deter-
`More than a year later, in December 1997,
`Genentech announced “favorable” prelimi-
`mined and exacting scientific research that
`nary results of phase III clinical
`trials.
`began on Raab‘s watch. Under Ievinson’s
`Levinson declared that
`the studies “have
`leadership. Genentech has also developed a
`knack for cooperation with the cancer com—
`shown that the Herceptin monoclonal anti-
`body may result in both slowing the progres-
`munity and a cool capacity for taking advan—
`sion of the cancer and increasing the percent-
`tage of a changing regulatory climate.
`As early as the mid—19805, attempts to use
`age ofwoman who experience tumor shrink—
`monoclonal
`antibodies
`to treat
`cancer
`age.” He was careful to add that Herceptin
`was “not a cure,” but emphasized that the
`seemed promising. Early efforts to make
`monoclonal antibodies involved injecting
`encouraging results suggested that “better
`control of the disease is possible." In short
`antigens into mice on the theory that the
`resultant antibodies would block cancerous
`order the company announced that it would
`file with the FDA for fast track approval of
`cell growth. These attempts failed due to the
`Herceptin, taking advantage of a new law
`unanticipated fact that bits of protein mole—
`cule from the mice acted as antigens in
`passed by Congress earlier that year.
`From that point on, the pace picked up
`humans, triggering immune responses that
`considerably. This past March, Genentech
`destroyed any therapeutic effects.
`NATURE BIOTECHNOLOGY VOLUME 16 OCTOBER 1998
`
`announced a deal with DAKO AIS (Glostrup,
`Denmark) to develop a diagnostic kit
`to
`screen patients for overexpression of the
`HERZ receptor for FDA approval. In May, the
`FDA granted fast track status to Herceptin.
`The fast
`track application, said Levinson,
`marked “a massive effort on the part of
`Genentech, the clinical trial investigators and
`staff, breast cancer advocates, researchers and
`the FDA to evaluate this novel treatment as
`rapidly as possible.”
`Two weeks later, on May 17, the prelimi-
`nary data from the phase III clinical trials
`were reported at the annual meeting of the
`American Society on Clinical Oncology.
`They were
`impressive
`(Nat. Biotechnol.
`16:615, 1998). The randomized. controlled
`study of 469 women with metastatic breast
`cancer showed that 28% of women treated
`with Herceptin showed no progression ofthe
`disease for 7.6 months after treatment began,
`compared with 4.6 months for chemothera-
`py alone—a dramatic 65% increase.
`Combining Herceptin with chemothera»
`py resulted in tumor shrinkage of 50% or
`more in 49% of the patients, compared to
`32% in patients who underwent chemother-
`apy alone. The results were particularly
`encouraging
`in
`combination
`with
`chemotherapy using paclitaxel, a form of
`taxol. A second study of 222 patients found
`that 16% of women, who had been previous—
`ly treated with conventional chemotherapies,
`showed major tumor reductions for nine
`months after using Herceptin alone.
`Although last month’s favorable recom-
`mendation by the FDA’s Oncologic Drugs
`Advisory Committee is not binding, most
`observers
`expect
`the FDA to approve
`Herceptin
`for
`commercialization
`by
`November. Right now,
`the reality is that
`breast cancer patients who overproduce
`HERZ can now expect to live some 10 to 12
`months after metastasis begins, a horribly
`rapid progression compared to six or seven
`years for HERZ—normal patients. Genentech
`has teamed up with the National Cancer
`institute to expand its Herceptin access pro-
`gram across the nation and has vowed to pro-
`duce an “adequate” supply of the drug by this
`[all anticipating FDA approval.
`As anyone familiar with terminal cancer
`knows, a few extra months of coherent, pain—
`free life is tantamount to the Holy Grail.
`Barring any surprises. Genentech’s Levinson
`should be credited for showing the pharma-
`ceutical biotechnology industry how to get
`the job done.
`M
`887
`
`(cid:43)(cid:82)(cid:86)(cid:83)(cid:76)(cid:85)(cid:68)(cid:3)(cid:89)(cid:17)(cid:3)(cid:42)(cid:72)(cid:81)(cid:72)(cid:81)(cid:87)(cid:72)(cid:70)(cid:75)(cid:3)
`Hospira v. Genentech
`(cid:44)(cid:51)(cid:53)(cid:21)(cid:19)(cid:20)(cid:26)(cid:16)(cid:19)(cid:19)(cid:27)(cid:19)(cid:24)(cid:3)
`IPR2017-00805
`(cid:42)(cid:72)(cid:81)(cid:72)(cid:81)(cid:87)(cid:72)(cid:70)(cid:75)(cid:3)(cid:40)(cid:91)(cid:75)(cid:76)(cid:69)(cid:76)(cid:87)(cid:3)(cid:21)(cid:19)(cid:23)(cid:24)
`Genentech Exhibit 2045
`
`
`'ll'fii‘) © 1998 Nature Publishing Group http://www.nature.com/naturebiotechnology
`COMMENTARY
`
`l
`Genentech is poised—for an anti—cancer breakthrough
`
`Russ Hoyle
`
`For the better part of a decade, the excite-
`Ever since the freewheeling G. Kirk Raab was
`room over monoclonal
`therapies cooled.
`forced to step down three years ago as head of
`Genentech (S. San Francisco, CA), his succes-
`Then researchers figured out how to replace
`the problematic mouse-contaminated por-
`sor Arthur D. Levinson has been under pres-
`tions ofmolecules with replacement material
`sure to beef up the company’s research and
`from human proteins. Genentech’s new
`development programs and produce exciting
`“humanized”
`experimental monoclonal
`new product lines.
`antibody therapy targeted the growth factor
`Levinson has gotten off to a good start.
`receptor gene HERZ/neu, which was known
`Genentech, which was bought out by
`to proliferate on the surface of cancerous
`Hoffman-LaRoche (Basel)
`in l990, began
`breast tissue cells in deadly late-stage cases of
`marketing Rituxin,
`the
`only federally
`the disease. The antibody worked by attach-
`approved monoclonal antibody for the treat-
`ment of cancer.
`last November. With the
`ing itself to the HERZ receptor, blocking the
`announcement this September that a US
`genetic signals that cause diseased cells to
`reproduce and in some cases killing off the
`Food and Drug Administration (FDA;
`cancer cells.
`Rockville, MD) advisory committee voted to
`approve Genentech’s experimental Herceptin
`The potential market was small. but in
`dire need. Some 1.6 million American
`monoclonal
`antibody,
`Levinson
`and
`women currently have breast cancer. There
`Genentech are now poised for another
`are 180,000 new cases in the U.S. each year.
`impressive therapeutic breakthrough for
`Of the roughly 164,000 metastatic cases.
`late-stage treatment of breast cancer. The
`some 25—30% involved overexpression of the
`FDA is expected to approve Herceptin by the
`end of the year.
`HERZ gene. As early as 1995, Genentech was
`For Levinson, the timing could not be
`swamped by demand for the highly targeted,
`yet—to—be-approved new drug and teamed up
`more serendipitous. When he took over the
`with patient advocacy groups to design a lot»
`company in 1995, what was then known as
`tery system to equitably distribute a limited
`Herz was among the hottest new properties
`supply of the investigational drug to severely
`in Genentech’s pipeline. It was also believed
`affected patients.
`that Levinson’s fate would probably depend
`on
`how successfully
`he
`beefed
`up
`But it wasn’t until 1996, less than a year
`after Levinson had taken the reins from Raab,
`Genentech’s flagging research programs and
`that Genentech announced favorable results
`brought
`innovative new pharmaceutical
`of the initial tests of its experimental therapy.
`products to market. Under the terms of the
`At an April scientific meeting, Genentech
`buyout, Hoffman-LaRoche, which owns
`67% of Genentech,
`is due to exercise its
`clinical researcher Thomas 'IWadell reported
`that 5 of44 women treated with the new anti~
`option to purchase 100% of the company
`next year.
`HERZ antibody alone experienced significant
`tumor reduction. In combination with other
`The development of an effective mono-
`chemotherapy, positive responses occurred in
`clonal antibody targeting the HERZ onco—
`nine out of 36 cases, or 25% ofthose treated.
`gene, a marker for the fatal spread of late-
`term breast cancer, has been a result of deter-
`More than a year later, in December 1997,
`Genentech announced “favorable” prelimi-
`mined and exacting scientific research that
`nary results of phase III clinical
`trials.
`began on Raab‘s watch. Under Ievinson’s
`Levinson declared that
`the studies “have
`leadership. Genentech has also developed a
`knack for cooperation with the cancer com—
`shown that the Herceptin monoclonal anti-
`body may result in both slowing the progres-
`munity and a cool capacity for taking advan—
`sion of the cancer and increasing the percent-
`tage of a changing regulatory climate.
`As early as the mid—19805, attempts to use
`age ofwoman who experience tumor shrink—
`monoclonal
`antibodies
`to treat
`cancer
`age.” He was careful to add that Herceptin
`was “not a cure,” but emphasized that the
`seemed promising. Early efforts to make
`monoclonal antibodies involved injecting
`encouraging results suggested that “better
`control of the disease is possible." In short
`antigens into mice on the theory that the
`resultant antibodies would block cancerous
`order the company announced that it would
`file with the FDA for fast track approval of
`cell growth. These attempts failed due to the
`Herceptin, taking advantage of a new law
`unanticipated fact that bits of protein mole—
`cule from the mice acted as antigens in
`passed by Congress earlier that year.
`From that point on, the pace picked up
`humans, triggering immune responses that
`considerably. This past March, Genentech
`destroyed any therapeutic effects.
`NATURE BIOTECHNOLOGY VOLUME 16 OCTOBER 1998
`
`announced a deal with DAKO AIS (Glostrup,
`Denmark) to develop a diagnostic kit
`to
`screen patients for overexpression of the
`HERZ receptor for FDA approval. In May, the
`FDA granted fast track status to Herceptin.
`The fast
`track application, said Levinson,
`marked “a massive effort on the part of
`Genentech, the clinical trial investigators and
`staff, breast cancer advocates, researchers and
`the FDA to evaluate this novel treatment as
`rapidly as possible.”
`Two weeks later, on May 17, the prelimi-
`nary data from the phase III clinical trials
`were reported at the annual meeting of the
`American Society on Clinical Oncology.
`They were
`impressive
`(Nat. Biotechnol.
`16:615, 1998). The randomized. controlled
`study of 469 women with metastatic breast
`cancer showed that 28% of women treated
`with Herceptin showed no progression ofthe
`disease for 7.6 months after treatment began,
`compared with 4.6 months for chemothera-
`py alone—a dramatic 65% increase.
`Combining Herceptin with chemothera»
`py resulted in tumor shrinkage of 50% or
`more in 49% of the patients, compared to
`32% in patients who underwent chemother-
`apy alone. The results were particularly
`encouraging
`in
`combination
`with
`chemotherapy using paclitaxel, a form of
`taxol. A second study of 222 patients found
`that 16% of women, who had been previous—
`ly treated with conventional chemotherapies,
`showed major tumor reductions for nine
`months after using Herceptin alone.
`Although last month’s favorable recom-
`mendation by the FDA’s Oncologic Drugs
`Advisory Committee is not binding, most
`observers
`expect
`the FDA to approve
`Herceptin
`for
`commercialization
`by
`November. Right now,
`the reality is that
`breast cancer patients who overproduce
`HERZ can now expect to live some 10 to 12
`months after metastasis begins, a horribly
`rapid progression compared to six or seven
`years for HERZ—normal patients. Genentech
`has teamed up with the National Cancer
`institute to expand its Herceptin access pro-
`gram across the nation and has vowed to pro-
`duce an “adequate” supply of the drug by this
`[all anticipating FDA approval.
`As anyone familiar with terminal cancer
`knows, a few extra months of coherent, pain—
`free life is tantamount to the Holy Grail.
`Barring any surprises. Genentech’s Levinson
`should be credited for showing the pharma-
`ceutical biotechnology industry how to get
`the job done.
`M
`887
`
`(cid:43)(cid:82)(cid:86)(cid:83)(cid:76)(cid:85)(cid:68)(cid:3)(cid:89)(cid:17)(cid:3)(cid:42)(cid:72)(cid:81)(cid:72)(cid:81)(cid:87)(cid:72)(cid:70)(cid:75)(cid:3)
`Hospira v. Genentech
`(cid:44)(cid:51)(cid:53)(cid:21)(cid:19)(cid:20)(cid:26)(cid:16)(cid:19)(cid:19)(cid:27)(cid:19)(cid:24)(cid:3)
`IPR2017-00805
`(cid:42)(cid:72)(cid:81)(cid:72)(cid:81)(cid:87)(cid:72)(cid:70)(cid:75)(cid:3)(cid:40)(cid:91)(cid:75)(cid:76)(cid:69)(cid:76)(cid:87)(cid:3)(cid:21)(cid:19)(cid:23)(cid:24)
`Genentech Exhibit 2045
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
